On September 3, 2019 DiaMedica Therapeutics Inc. (Nasdaq: DMAC) reported that management will present at the 2019 Dougherty & Co. Institutional Investor Conference in Minneapolis, Minnesota (Press release, DiaMedica, SEP 3, 2019, View Source [SID1234539189]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rick Pauls, President and CEO of DiaMedica Therapeutics will host one-on-one institutional investor meetings throughout the day at the event.

Dougherty & Co. Institutional Investor Conference
Date: Thursday, September 5, 2019
Location: Millennium Hotel (1313 Nicollet Mall, Minneapolis, MN 55403)

On September 3, 2019 CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, reported that senior management will participate in three investor conferences in September, including Citi’s 14th Annual Biotech Conference, H.C. Wainwright 21st Annual Global Investment Conference and Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies (Press release, CymaBay Therapeutics, SEP 3, 2019, View Source [SID1234539188]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 14th Annual Biotech Conference
Date: Thursday, September 5
Time: 12:45pm Eastern Time
Format: Panel: Living it Up with the Liver Disease Players – Views on NASH, PBC, etc.
Webcast: View Source

H.C. Wainwright 21st Annual Global Investment Conference
Date: Tuesday, September 10
Time: 9:10am Eastern Time
Format: Corporate Presentation
Webcast: View Source

Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies
Date: Tuesday, September 24
Time: 8:00 am Eastern Time
Format: 1:1 Meetings Only

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 3, 2019 BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) reported that the company will present at the H.C. Wainwright Global Investment Conference in New York on Monday, September 9, 2019 at 9:10 a.m. ET (Press release, BioCryst Pharmaceuticals, SEP 3, 2019, View Source [SID1234539186]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

On September 3, 2019 ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, reported its participation in the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. LLC (Press release, ProMIS Neurosciences, SEP 3, 2019, View Source [SID1234539185]). The conference is being held September 8-10, 2019 at the New York Palace Hotel in New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ProMIS’ Executive Chairman, Eugene Williams will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS (amyotrophic lateral sclerosis) Tuesday, September 10th at 10:25 am ET. The audio webcast and slides of Mr. Williams’ presentation will be archived and available on ProMIS’ web site and through the following link View Source